T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.
Daniel Castellano,Arjun Vasant Balar,Peter H. O'Donnell,Petros Grivas,David J. Vaughn,Thomas Powles,Jacqueline Vuky,Jae-Lyun Lee,Yves Fradet,Joaquim Bellmunt,Miguel Angel Climent,Nicholas J. Vogelzang,Elizabeth R. Plimack,Howard Gurney,Noah M. Hahn,Cora N. Sternberg,Jin Zhi Xu,Kentaro Imai,Blanca Homet Moreno,Ronald de Wit +19 more
TL;DR: Although the number of pts who received retreatment was small, objective responses were observed and generally consistent with observations from retreatment in other tumor types (e.g., melanoma).
Journal ArticleDOI
Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455–6
Axel Bex,Thomas Powles +1 more
Journal ArticleDOI
Castration refractory prostate cancer: cinderella finally comes to the ball.
TL;DR: Abiraterone has shown that ‘androgen-independent’ or ‘hormone refractory’ disease is neither of these things and that androgen receptor signalling remains a relevant therapeutic target and a key area for current and future research.
Journal ArticleDOI
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: In response to a letter from Dr. Catalá-López
Thomas Powles,Naveed Sarwar,Robert Jones,Peter Wilson,Ekaterina Boleti,Andrew Protheroe,Simon J. Crabb,Jonathan Shamash,Andrew Stockdale,Louise Lim,Paul Nathan,Simon Chowdury +11 more
TL;DR: This poster presents a probabilistic procedure called a “cell reprograming” or “ ‘spatially aggregating’ cells’ to establish which cells secrete “foreign substance” that can be passed to the immune system and cause cancer.
Journal ArticleDOI
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.
Arlene O. Siefker-Radtke,Thomas Powles,Victor Moreno,Taek Won Kang,Irfan Cicin,Angela R Girvin,Sydney Akapame,Spyros Triantos,Anne O'Hagan,Wei Zhu,Meggan Tammaro,Yohann Loriot +11 more
TL;DR: In this article , ERDA+CET was used for first-line therapy for cisplatin (cis-ineligible pts with mUC to determine the potential impact in this setting (NCT03473743).